drugset / Trial / NCT00274690

Post-Operative Nausea And Vomiting Study In Female Patients

NCT00274690

Phase 2 Completed 435 enrolled GlaxoSmithKline
RandomizedParallel-groupDouble-blindPrevention

Summary

The primary purpose of this study is to determine an effective dose of this NK-1 anti-emetic medication to prevent nausea and vomiting in females after surgery.

Timeline

Start
2005-02
Primary completion
2005-08
Completion
2005-08

Drugs

EvaluationDrugModalityDoseRoute
Subject Casopitant Small molecule 50 mg Oral
Subject Casopitant Small molecule 150 mg Oral

Indications

No indication recorded.